Latest Tardive dyskinesia Stories

WASHINGTON, Aug. 15 /PRNewswire/ -- Prestwick Pharmaceuticals, Inc., a privately-held pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved XENAZINE(R) (tetrabenazine) for the treatment of chorea associated with Huntington's disease (HD). XENAZINE is the first and only FDA-approved treatment for any symptom of HD and is expected to be available later this year. "Until today, physicians and patients had no FDA-approved treatments for...

SAN DIEGO, May 22 /PRNewswire/ -- After administration of paliperidone extended-release (ER) tablets, blood levels of the drug were not affected when given with a common antidepressant, according to new data presented today at the 160th Annual Meeting of the American Psychiatric Association. Paroxetine, a selective serotonin reuptake inhibitor (SSRI), is an antidepressant known to interact with several antipsychotic medications. This new study showed there was no clinically significant...

WASHINGTON (Reuters) - Pozen Inc. said on Friday it would no longer pursue U.S. approval of its experimental migraine drug MT 100, one day after a U.S. advisory panel said another clinical trial was needed. Regulators had rejected the drug in May 2004 over concerns about the risk of users developing unusual tongue and mouth movements. MT 100 aimed to help migraine patients who do not have nausea. Instead, the North Carolina-based drugmaker said it will continue pursuing its other headache...